Opinions

Jason Del Vicario Chemed Corporation CHE-N PAST TOP PICK Mar 11, 2022

(A Top Pick Mar 08/21, Up 11%) Doesn't own stock anymore even though has recommended it to investors. Flawed corporate governance. Management overpaid. Will not buy in the future.

Jason Del Vicario

Unlock Rating

$470.250

Stock price when the opinion was issued

Healthcare

It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.

Get Signals Create your Watchlist

You might be interested:

TOP PICK

They have been around for over 100 years. They survived the depression. They have interests in hospices and cleaning. They have dental supply as well. They have a long history of raising dividends and buybacks. He'd like to see it lower before buying. (Analysts’ price target is $595.00)

BUY

She added more. The hospice business is growing double-digits.

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : hello@stockchase.com.

Jason Del Vicario Chemed Corporation CHE-N PAST TOP PICK Mar 11, 2022

You might be interested:

Chemed Corporation(CHE-N)

Chemed Corporation(CHE-N)

Latest Buy Signals

Today's Top Picks

Popular Articles

Latest Sell Signals

Most Recent Experts

Stockchase Insights

Rebecca Teltscher

Andrey Omelchak

The Panic-Proof Portfolio (Stockchase Research)

The Monthly Gems by Allan Tong